A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05298254 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

505

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Simplex

Interventions

BIOLOGICAL: Non-adjuvanted HSV formulation 1
BIOLOGICAL: Non-adjuvanted HSV formulation 2
BIOLOGICAL: Non-adjuvanted HSV formulation 3
BIOLOGICAL: HSV formulation 1 with adjuvant 1
BIOLOGICAL: HSV formulation 2 with adjuvant 1
BIOLOGICAL: HSV formulation 3 with adjuvant 1
BIOLOGICAL: HSV formulation 1 with adjuvant 2
BIOLOGICAL: HSV formulation 2 with adjuvant 2
BIOLOGICAL: HSV formulation 3 with adjuvant 2
DRUG: Placebo
BIOLOGICAL: HSVTI_F1
BIOLOGICAL: HSVTI_F2

Sponsor

GlaxoSmithKline